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Abstract 
Background: Variations in cardiac troponin concentrations by age, sex and time between 
samples in patients with suspected myocardial infarction are not currently accounted for in 
diagnostic approaches. We aimed to combine these variables through machine learning to 
improve the assessment of risk for individual patients. 
Methods: A machine learning algorithm (myocardial-ischemic-injury-index [MI3]) 
incorporating age, sex, and paired high-sensitivity cardiac troponin I concentrations, was 
trained on 3,013 patients and tested on 7,998 patients with suspected myocardial infarction. 
MI3 uses gradient boosting to compute a value (0-100) reflecting an individual’s likelihood of 
a diagnosis of type 1 myocardial infarction and estimates the sensitivity, negative predictive 
value (NPV), specificity and positive predictive value (PPV) for that individual. Assessment 
was by calibration and area under the receiver-operating-characteristic curve (AUC). 
Secondary analysis evaluated example MI3 thresholds from the training set that identified 
patients as low-risk (99% sensitivity) and high-risk (75% PPV), and performance at these 
thresholds was compared in the test set to the 99th percentile and European Society of 
Cardiology (ESC) rule-out pathways. 
Results: Myocardial infarction occurred in 404 (13.4%) patients in the training set and 849 
(10.6%) patients in the test set. MI3 was well calibrated with a very high AUC of 0.963 
[0.956-0.971] in the test set and similar performance in early and late presenters. Example 
MI3 thresholds identifying low-risk and high-risk patients in the training set were 1.6 and 49.7 
respectively. In the test set, MI3 values were <1.6 in 69.5% with a NPV of 99.7% 
(99.5%-99.8%) and sensitivity of 97.8% (96.7-98.7%), and were ≥49.7 in 10.6% with a PPV 
of 71.8% (68.9-75.0%) and specificity of 96.7% (96.3-97.1%). Using these thresholds, MI3 
performed better than the ESC 0/3-hour pathway (sensitivity 82.5% [74.5-88.8%], specificity 
92.2% [90.7-93.5%]) and the 99th percentile at any time-point (sensitivity 89.6% 
[87.4-91.6%]), specificity 89.3% [88.6-90.0%]). 
Conclusions: Using machine learning, MI3 provides an individualized and objective 
assessment of the likelihood of myocardial infarction, which can be used to identify low-risk 
and high-risk patients who may benefit from earlier clinical decisions. 
Clinical Trial Registration: Unique Identifier: Australian New Zealand Clinical Trials 
Registry: ACTRN12616001441404. URL: https://www.anzctr.org.au 
Key Words: Myocardial infarction; acute coronary syndrome; machine learning; troponin 
Non-standard Abbreviations and Acronyms 
AUC- area under the receiver-operating-characteristic curve 
CI- confidence intervals
MI3- myocardial-ischemic-injury-index
NPV- negative predictive value
PPV- positive predictive value
STEMI- ST-segment elevation myocardial infarction
URL- upper reference limit
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Clinical Perspective 
 
What is new? 
• In an international collaboration involving 11,011 patients from nine countries, we 
used machine learning to train and test a novel algorithm that estimates the probability 
of myocardial infarction for an individual patient. 
• The MI3 algorithm generates a value that takes into consideration age, sex, paired 
cardiac troponin I concentrations, and rate of change in troponin concentration, to 
estimate the negative and positive predictive value for each patient value associated 
with these measures. 
• This represents one of the first effective demonstrations of how machine learning 
could be used to guide clinical decision making in patients with suspected acute 
coronary syndrome. 
 
What are the clinical implications? 
• The MI3 algorithm is more versatile than existing algorithms as it is not dependent on 
fixed cardiac troponin thresholds, does not require serial testing to be performed at 
specific time points, and recognises that different healthcare systems have different 
priorities and tolerances of risk. 
• Prospective studies are now required to evaluate patient outcomes and resource 
utilisation following implementation of the MI3 algorithm into clinical practice. 
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Introduction 
The use of cardiac troponin testing in clinical practice is evolving rapidly.(1-3) Advances in 
assay analytical precision now permit quantification of cardiac troponin concentrations in the 
normal reference range with novel applications for early diagnostics and risk stratification in 
patients being assessed for possible acute coronary syndromes.(4) Historically, international 
guidelines have recommended the use of serial cardiac troponin measurements over 6 to 12 
hours to define myocardial infarction in patients with a rise and/or fall in cardiac troponin 
concentration where at least one of the serial measured concentrations is above the 99th 
percentile.(5,6) However, some studies have challenged this approach suggesting lower 
thresholds can risk stratify patients to low, intermediate, or high risk of myocardial infarction 
when using high-sensitivity cardiac troponin assays.(7-15) These strategies have been 
incorporated into accelerated diagnostic pathways that advocate earlier troponin measurement 
at presentation and 1 to 3 hours later to facilitate prompt diagnosis and treatment in those 
with myocardial infarction or to expedite discharge in those without.(16,17) 
 The performance of these pathways varies across different populations, reflecting 
variation in cardiac troponin concentrations with age and sex.(13,18-21) This heterogeneity is 
not reflected in strategies which advocate the use of fixed thresholds for all patients, which 
only allow classification of patients as low, intermediate, or high risk and that do not reflect 
more subtle variations in risk.(6) Machine learning has been advocated as an objective, 
replicable, approach to integrate multiple quantitative variables to improve diagnostic 
accuracy.(22,23) Our aim was to test an algorithm, the myocardial-ischemic-injury-index 
(MI3), which had been trained by machine learning to estimate an individual patient’s 
likelihood of myocardial infarction. 
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Methods 
Transparency and Openness Promotion 
The analysis code for this study is available on request. The algorithm is proprietary and 
subject to a patent application, however we are able to share this with researchers who agree 
to using the algorithm only for research purposes with a data sharing agreement. 
Study design 
This was an analysis of prospectively collected data from multiple centers to train and test the 
MI3 algorithm to predict the diagnosis of type 1 myocardial infarction. The training set 
comprised data from two cohorts (14,24) and the test set comprised data from seven cohorts 
of patients attending the Emergency Department with suspected myocardial 
infarction.(15,25-29) Training and testing are the nomenclature of machine learning, and are 
analogous to derivation and validation in studies of new diagnostic biomarkers. 
MI3 incorporates age, sex, paired cardiac troponin I concentrations at presentation and 
at another early, yet flexible, time point, and rate of change of cardiac troponin I 
concentration. These variables (features) were selected a priori because they are a) objective 
and automatically captured from electronic hospital records, b) include serial measurements 
as recommended by guidelines, and c) associated with the diagnosis of myocardial infarction. 
MI3 computes a value from 0-100 (the MI3 value), which reflects the likelihood of a diagnosis 
of type 1 myocardial infarction for each patient during hospitalization (higher values indicate 
greater likelihood). The algorithm uses an embedded reference table to report for each 
individual patient estimates of sensitivity, negative predictive value (NPV), specificity and 
positive predictive value (PPV) of the diagnosis for a given MI3 value.  MI3 was developed 
on the training data set by Abbott Diagnostics using a machine learning technique called 
gradient boosting. This technique iteratively trains a set of sequential weak learners (here 
decision trees) using the provided features to map onto the outcome (whether the patient was 
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or was not diagnosed with myocardial infarction). For further details regarding the gradient 
boosting method see also Supplement.(30) This is analogous to, but more complex than, the 
beta-coefficient weightings of a logistic regression model. The algorithm was provided to an 
independent statistician [JP] who evaluated its performance in the test set. JP had full access 
to all the test set data and takes responsibility for its integrity and the analysis. 
 We report according to relevant sections of the Transparent Reporting of 
multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD) 
statement.(31) The study was registered on the Australian New Zealand Clinical Trials 
Registry; ACTRN12616001441404. 
Participants and cohorts 
Patients presenting with symptoms suggestive of myocardial infarction in whom serial 
cardiac troponin measurements were obtained were included. Patients with ST-segment 
elevation myocardial infarction (STEMI) at presentation were excluded. Cohorts were 
identified for inclusion if they were prospective, had cardiac troponin I concentrations 
measured with the Abbott ARCHITECTSTAT high-sensitivity assay (Abbott Diagnostics, 
Chicago, Illinois) at presentation and at a second time point approximately 1-3 hours later 
(details in the Supplement Materials), the final diagnosis was adjudicated according to the 
Universal Definition of Myocardial Infarction (5), and ethical approval permitted sharing of 
individual patient-level data (Supplemental Table 1). All cohort studies were conducted in 
accordance with the Declaration of Helsinki and approved by the local research ethics 
committee or institutional review board. Written informed consent was obtained where this 
was required. All adjudication was completed prior to development of the MI3 algorithm. 
Outcome definitions and adjudication 
The primary outcome was the adjudicated diagnosis of type 1 myocardial infarction during 
the index admission. Although high-sensitivity cardiac troponin I was measured in all 
D
ow
nloaded from
 http://ahajournals.org by on August 22, 2019
10.1161/CIRCULATIONAHA.119.041980 
7 
patients, other cardiac troponin assays were used for adjudication in some cohorts 
(Supplemental Table 1). 
Algorithm development 
A gradient boosting model was developed using pre-defined features (age, sex, paired cardiac 
troponin I concentrations at presentation and at another early, yet flexible, time point, and 
rate of change of cardiac troponin I concentration) to estimate the likelihood of a diagnosis of 
type 1 myocardial infarction.  Once the model was trained, it was used to generate MI3 values 
for each patient in the test sets. 
Statistical analysis 
Primary analysis 
We describe algorithm performance in the test set by 1) visual inspection of a calibration 
curve to show how accurately MI3 values estimate the likelihood of myocardial infarction, 
and 2) by the area under the receiver-operating-characteristic curve (AUC) to quantify how 
well the MI3 values discriminated between those with and without myocardial infarction. 
Additionally, we compared diagnostic metric outputs from the algorithm (sensitivity, NPV, 
specificity, and PPV) for each patient with the metrics determined in the test set using each 
individuals MI3 value as a threshold. 
Secondary analyses 
MI3 is designed to be used as a continuous measure.  However, we recognize that in this field 
most tools rely on thresholds to guide clinical decisions. Therefore, as illustrative examples 
of how an individual hospital may choose to use MI3, we demonstrate its diagnostic 
performance at two exemplar MI3 value thresholds. First, we determined the MI3 values with 
their 95% confidence interval that gave a sensitivity ≥99.0% or NPV ≥99.5% in the training 
set and assessed the accuracy of these example threshold values in the test set. These 
diagnostic criteria were pre-specified and based on an international survey of acceptable risk 
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by Emergency Department physicians (32), and prior prospective studies defining risk 
stratification thresholds for high-sensitivity cardiac troponin (14). Second, we determined the 
MI3 values that gave a specificity ≥90% and a PPV ≥75% in the training set based on 
consensus of the project steering committee, and assessed their performance in the test set. 
We used 1,000 bootstrapped samples to determine these MI3 thresholds and their 95% 
confidence intervals. All analyses were performed in R (Version 3.2.4: The R Foundation for 
Statistical Computing). 
Additional analyses 
Pre-specified subgroup analyses were performed by age, sex, co-morbidities (coronary artery 
disease, diabetes mellitus, hypertension, current smoking), time from symptom onset to first 
sample draw, time between tests, and the presence or absence of myocardial ischemia on the 
electrocardiogram. Performance of the algorithm was also evaluated for the outcomes of type 
1 myocardial infarction within the next 30 days and for type 1 or 2 myocardial infarction on 
index admission.  Finally, we compared the performance of MI3 using the example thresholds 
derived from our training set with the 99th percentile at any time-point, and the European 
Society of Cardiology (ESC) 0/1-hour and 0/3-hour pathways (6) for a diagnosis of type 1 
myocardial infarction in our test set. 
 
Results 
The training set comprised 3,013 patients of whom 404 (13.4%) had a diagnosis of type 1 
myocardial infarction. The set was predominantly male (63%) with a mean age of 62.4 years 
(Table 1). The test set comprised 7,998 patients, 62% male with a mean age of 58.8 years and 
mean time between samples of 2.5 hrs (standard deviation 1.2 hrs). Of these patients, 849 
(10.6%) had a diagnosis of type 1 myocardial infarction. There were no missing data for any 
of the variables used in the training and testing sets. Patients in the testing set were younger, 
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less likely to have known coronary artery disease, but more likely to smoke cigarettes, have 
diabetes mellitus, dyslipidemia, or a family history of coronary artery disease than those in 
the training set. 
Primary analysis: calibration and discrimination 
The MI3 algorithm was well calibrated and discriminated between those with and without 
type 1 myocardial infarction (AUC 0.963 [95% CI 0.957-0.968], Figure 1). Compared to the 
MI3 output estimated metrics, the sensitivity was similar, specificity and NPV were slightly 
higher, and the PPV marginally lower in the test set (Supplemental Figure 1). 
There was no difference in AUCs for those presenting within 3 hours (0.966 [0.959-
0.973]) compared to later presenters (0.965 [0.959-0.972]) and no difference when stratifying 
by sex  (men 0.962 [0.955-0.969] and women 0.962 [0.952-0.973], Supplemental Figure 2). 
The AUCs were higher in patients with no prior history of coronary artery disease, diabetes 
mellitus or hypertension compared to patients with these co-morbidities. The AUC was 
higher in younger compared to older patients and in those with no myocardial ischemia on 
the ECG compared to those with ischemia. 
Secondary analysis: example diagnostic thresholds 
The MI3 threshold values from the training set that corresponded to our pre-specified 
diagnostic performance metrics were 1.6 (0.9-3.0; sensitivity ≥99.0%), 3.1 (1.7-4.7; NPV 
≥99.5%), 17.2 (13.8-21; specificity ≥90.0%), and 49.7 (36.6-60.0; PPV ≥75%, Table 2). In 
the test set, MI3 values of 1.6 and 3.1 gave a sensitivity of 97.8% (96.7-98.7%) and a NPV of 
99.4% (99.2-99.6%), respectively. MI3 values of 17.2 and 49.7 gave a specificity of 91.7% 
(91.1-92.3%) and a PPV of 71.8% (68.9-75.0%) (Table 2). 
If, for example, patients with MI3 values <1.6 were to be classified as low-risk of 
myocardial infarction then this threshold would identify 69.4% (68.4%-70.4%) as low-risk of 
whom 0.5% (0.3%-0.7%) would be false negatives. If patients with MI3 values ≥49.7 were 
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classified as high-risk then this threshold would identify 10.6% (10.0%-11.2%) as high risk 
of whom 28.1% (25.1% to 31%) would be false positives (Supplemental Table 2). These two 
exemplar thresholds were used for all subsequent analysis. The MI3 threshold value of 1.6 
performed similarly across all subgroups including those who presented within 3 hours of 
symptom onset (sensitivity 98.7% [97.3%-100%] and NPV 99.8% [99.7%-100%], 
Supplemental Figure 3). The MI3 threshold value of 49.7 also performed similarly across 
most groups with the exception of sex and time from symptom onset, where the PPV was 
lower in women than men, and in those presenting within 3 hours compared-those presenting 
more than 3 hours from symptom onset (Supplemental Figure 4). 
Secondary analysis: type 1 myocardial infarction within 30 days 
In addition to the 849 (10.6%) patients with type 1 myocardial infarction during the initial 
hospitalization there were 23 (2.9%) with myocardial infarction following discharge within 
the next 30 days. The MI3 value discriminated between those patients with and without type 1 
myocardial infarction within the next 30 days with an AUC of 0.957 (0.951-0.963). 
Threshold values of 1.6 and 49.7 gave a sensitivity of 96.6% (95.3-97.8%) and PPV of 71.9% 
(69.0-74.9%), respectively (Supplemental Table 2). 
Secondary analysis: type 1 or 2 myocardial infarction on presentation 
In addition to the 849 (10.6%) patients with type 1 myocardial infarction there were 216 
(2.7%) with type 2 myocardial infarction during the initial hospitalization. The MI3 value 
discriminated between those with and without type 1 or type 2 myocardial infarction with an 
AUC of 0.963 (0.957-0.968, Supplemental Figure 5). The example low-risk MI3 threshold, 
1.6, had a sensitivity of 97.4% (96.3-99.5%), and an NPV of 99.5% (99.3-99.7%], identifying 
69.5% of patients as low-risk. The example high-risk threshold, 49.7, had a specificity of 
97.7% (97.3-98.0%), and a PPV of 80.8% (78.1-83.5%), identifying 10.6% of patients as 
high-risk (Supplemental Table 3). 
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Secondary analysis: comparison with other recommended diagnostic strategies 
In all 7,998 patients in the test set, the 99th percentile upper reference limit at any time-point 
identified 6,473 (80.9%) patients as low-risk (NPV 98.6% [98.3-98.9%], sensitivity 89.6% 
[87.4-91.6%]) and 1,525 (19.1%) as high-risk (PPV 49.9% [47.4-52.4%], specificity 89.3% 
[88.6-90.0%]). A total of 1,652 patients (21%) from the test set were eligible for inclusion in 
the analysis of the ESC 0/3-hour pathway with ≥2.5 hours between serial samples (Figure 2). 
This pathway identified 86.7% (1,433/1,652) of patients as low-risk (NPV 98.5% [97.8-
99.1%], sensitivity 82.5% [74.5-88.8%]) with 21 missed events, and 13.3% (219/1,652) of 
patients as high-risk (PPV 45.2% [38.5-52.1%], specificity 92.2% [90.7-93.5%]). In the same 
patient group, MI3 <1.6 or ≥49.7, identified 70.7% (1,168/1,652) of patients as low-risk 
(NPV 99.9% [99.5-100%], sensitivity 99.2% [95.4-100%]) with one missed event, and 9.0% 
(149/1,652) of patients as high-risk (specificity 95.9% [94.8-96.8%], PPV 57.7 [49.4-65.8%]) 
respectively. Use of these thresholds identified 20.3% (335/1,652) of patients as intermediate 
risk (MI3 1.6 to 49.6) of whom 33 patients had an event. 
Only 336 patients (4%) from the test set were eligible for inclusion in the analysis of 
the ESC 1-hour pathway with >0.5 hour but ≤1.5 hours between serial samples (Figure 3). 
This pathway identified 54.3% (183/336) of patients as low-risk (NPV 100% [98.0-100%], 
sensitivity 100% [93.2-100%]) with no missed events, and 18.3% (61/336) of patients as 
high-risk (PPV 75.4% [62.7-85.5%], specificity 94.7% [91.4-97.0%]), and 27.4% (92/336) of 
patients as intermediate risk of whom 6 had an event. Here MI3 <1.6 or ≥49.7, identified 
64.3% (216/336) of patients as low-risk (NPV 100% [98.3-100%], sensitivity 100% [93.2-
100%]) with no missed events, and 14.9% (50/336) of patients as high-risk (specificity 97.2% 
[94.5-98.8%], PPV 84.0 [70.9-92.8%]) respectively. Use of these thresholds identified 20.8% 
(70/336) of patients as intermediate risk (MI3 1.6 to 49.6) of whom 10 patients had an event. 
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Discussion 
In a large, international, multi-centre study of over 11,000 patients with suspected myocardial 
infarction, we used machine learning to train and test a novel decision tool that incorporates 
simple, objective variables known to be associated with the diagnosis of myocardial 
infarction to accurately predict the likelihood of a diagnosis of myocardial infarction. The 
algorithm was well calibrated, and the overall diagnostic performance was identical in both 
training and test data sets. This study has several unique and important characteristics. 
First, this technique provides an individualised and precise assessment of risk by 
using age, sex, and paired high-sensitivity cardiac troponin I concentrations and allows for 
the complex and non-linear ways in which these variables may interact. This is in contrast to 
contemporary algorithms in clinical use which are based on fixed time-points for sampling, 
fixed troponin thresholds, and do not account for any interaction between input variables. 
One exception is the Troponin only-Manchester Acute Coronary Syndrome rule which uses a 
logistic regression model to provide risk estimates for myocardial infarction, incorporating 
age, sex, multiple clinical variables, and a single high-sensitivity troponin T 
measurement.(33,34)  They reported an AUC of 0.90. This model has a number of strengths, 
but does not take into account dynamic interaction between variables and has to-date only 
been assessed using thresholds allocating patients into one of four risk categories.(35,36) 
Second, MI3 recognises the importance of both the magnitude and rate of change in 
cardiac troponin concentration for the diagnosis of myocardial infarction, without applying a 
fixed absolute or percentage change in concentration, or mandating specific time-points for 
serial testing. MI3 performed well across a range of time intervals between sampling. This 
enhances its transferability because variation in the sample timing is commonplace in busy 
Emergency Departments. Importantly, there was no difference in performance when stratified 
by time from symptom onset, which means that unlike some other approaches, MI3 can be 
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applied in those patients presenting early (i.e. within 3 hours of symptom onset). This is 
important because early presenters are a sizable subset of patients (34% of patients in the test 
cohort) and also because the time of symptom onset is often uncertain. 
Third, the large cohort size and number of patients with type 1 myocardial infarction 
allowed for a robust analysis of sub-groups. 
Fourth, at the example thresholds MI3 was better than the 99th percentile alone or the 
ESC 0/3-hour pathway at identifying low-risk and high-risk patients. Consistent with 
previous reports, (18,20,21) both of these approaches gave a low diagnostic sensitivity and 
poor positive predictive value despite being widely used in clinical practice (37). MI3 
compared well to the ESC 0/1-hour pathway, with the primary advantage of MI3 being 
flexibility in the timing of serial testing, and the simplicity of using probabilities rather than 
multiple thresholds to stratify risk in individual patients. 
Fifth, the algorithm performed well even when type 2 myocardial infarction was 
included as an outcome event. 
Finally, MI3 provides guidance on high-risk patients reporting the PPV and specificity 
for type 1 myocardial infarction that could be used to initiate earlier treatment or expedite 
cardiology consultation. Previous attempts to optimise specificity for myocardial infarction 
have used absolute or relative changes in troponin concentrations to differentiate from 
chronic myocardial injury or have recommended thresholds well above the 99th 
percentile.(16,17,19,38) MI3 avoids the need to decide on the use of relative or absolute 
changes or on a threshold for change a priori. In essence, the developed machine-learning 
model uses the rate of concentration change, patient age, and sex to decide on the weighting 
of relative and absolute troponin concentration changes. 
These features are presented to the gradient boosting algorithm which outputs the MI3 
value which can provide a clinical decision support tool for the assessment of all patients 
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with suspected myocardial infarction. The clinical decision support tool also reports the 
diagnostic parameters associated with the calculated MI3 value. These diagnostic parameters 
cannot be derived for an individual patient, and therefore the tool uses an embedded reference 
table to report estimates of sensitivity, specificity and negative and positive predictive values 
from our training set alongside the calculated MI3 value. This tool is easy to implement in 
practice, is objective, because it does not rely on potentially inconsistent assessment of 
symptoms or patient history, and provides accurate estimates of the likelihood of myocardial 
infarction for each individual patient to aid clinical decision making. 
We are aware of two attempts to use machine learning in this field, both using an 
artificial neural network. Green and colleagues in 2005 developed a model for predicting 
acute coronary syndrome based on demographics, prior history, symptom duration, and 
diastolic blood pressure.(39) This model had an AUC of 0.778.  In 2007, a model based on 
serial measurements of myoglobin and contemporary troponin I concentrations, either alone 
or in combination with their rate of change was evaluated in 310 patients.(40) The output of 
this algorithm was dichotomised for diagnostic purposes, such that it had a sensitivity of 
99%. These pioneering efforts were undertaken before the availability of high-sensitivity 
troponins and prior to the availability of multiple high-quality cohorts that we have been able 
to draw on. 
Finally, most studies that have developed or assessed strategies to risk stratify patients 
with suspected myocardial infarction have enrolled a limited number of patients with a small 
number of events resulting in limited precision and therefore limited external generalizability. 
In contrast, MI3 has been trained and tested in a population that includes patients from nine 
studies across multiple geographic regions with over 1,250 events, and significant variation 
in the prevalence of disease, suggesting this approach is generalizable and could be used in 
any healthcare setting worldwide. Furthermore, rather than being an inflexible diagnostic 
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strategy with multiple set thresholds, the MI3 algorithm is a dynamic tool that in the future 
could be retrained for individual health care settings depending on disease prevalence and 
diagnostic priorities to facilitate healthcare delivery. 
From a clinical perspective, each patient will have an MI3 value that takes into 
consideration their own age and sex and measured cardiac troponin concentrations. This 
approach is distinct from previous algorithms. Whilst early diagnostic pathways, such as the 
ESC 0/1-hour pathway, identify groups of patients with high negative and moderate positive 
predictive value, they do not report these metrics or derive them for individual patients. This 
is a particularly important limitation for the one third of patients triaged to the observe zone, 
for whom the 0/1 hour pathway provides no guidance. The MI3 algorithm is also more 
versatile because it does not require serial testing to be performed at specific timepoints, and 
recognises that different healthcare systems have different priorities and tolerances of risk. 
The MI3 algorithm allows implementation to be tailored accordingly. For example, in some 
more conservative institutions triage to out-patient investigation might be acceptable only 
where the NPV is >99.8% (false negative rate of 1 in 1,000; see Figure 4). Similarly, a 
cardiology consultation in the Emergency Department might be triggered if the PPV of 
myocardial infarction is >60%, but direct transfer to the cardiac cath lab only considered 
where the PPV is >80%.  Prospective studies are now required to evaluate patient outcomes 
and resource utilisation following implementation of this algorithm into clinical practice. 
Limitations 
Not all sites used the high-sensitivity cardiac troponin I assay to adjudicate the diagnosis of 
myocardial infarction, with several sites using either contemporary assays or high-sensitivity 
cardiac troponin T assays. This should reduce performance of the algorithm, yet we observed 
little heterogeneity across the cohorts. The choice of the high-risk example threshold was pre-
specified on the basis of the PPV which is dependent on prevalence and may explain some of 
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the heterogeneity between cohorts. Institutions could choose their own threshold based on the 
local prevalence of myocardial infarction or clinical priorities. Factors such as acceptability 
of risk, availability of inpatient beds or outpatient services, or the need to transfer patients for 
coronary angiography may influence the adoption of local thresholds. In contrast to the ESC 
0/1- and 0/3-hour pathways, the primary purpose of MI3 is to assess risk in an individual 
patient. There are some limitations to our comparison with both pathways due to the 
requirement for precise sample intervals, which reduced the proportion of patients eligible for 
inclusion to 21% and 4% of our test cohort respectively. Prospective studies are needed to 
better understand the advantages and disadvantages of pathways based on individual 
probabilities rather than fixed thresholds. Finally, it is conventional in machine learning to 
use a larger data set to train and smaller data set to test out of practical considerations to 
develop a robust algorithmic model. We have used the smaller data set to train because it was 
available before the other data sets and because it was already a large data set. Machine 
learning also has the capability to utilize a large number of features which could include 
aspects of patient history and clinical symptoms. These variables were not included because 
our intention was to develop a tool that only uses variables that are objective and always 
available to ensure out algorithm can be applied widely in clinical practice. Finally, we focus 
on the training and testing of the MI3 algorithm and do not report a comparison with other 
linear regression or machine learning methods here. 
Conclusion 
The MI3 clinical decision support tool incorporates simple and objective variables including 
age, sex and serial cardiac troponin I concentrations measured using a high-sensitivity assay 
to rapidly estimate risk of myocardial infarction. It can be used to individualise the risk 
assessment of patients with suspected myocardial infarction or to categorize patients into 
low- or high-risk groups.  
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Table 1. Baseline characteristics of training and testing sets 
 
Variable Training (n=3,013) Testing (n=7,998) 
Age, years 62.4 ± 14.9 58.8 ± 15.1 
Sex, female (%) 1,113 (36.9) 3,058 (38.2) 
History of coronary artery disease (%) 1,143 (37.9) 2,143 (26.8) 
History of myocardial infarction (%) 630 (21.1) 1,599 (20.0) 
Diabetes mellitus (%) 436 (14.6) 1,494 (18.7) 
Dyslipidemia (%) 1,232 (41.3) 3,835 (47.9) 
Hypertension (%) 1,705 (57.2) 4,570 (57.1) 
Current smoker (%) 648 (21.9) 1,957 (24.7) 
Family history of coronary artery disease (%) 986 (33.9) 3,197 (40.6) 
Symptom onset to blood draw ≤3h (%) 1,065 (33.0) 3,613 (38.5) 
Time between blood draws, hours 1.2 [1.0-2.5] 
2.0 ± 1.9 
2.2[2.0-2.6] 
2.5 ± 1.2 
Values are mean ± standard deviation; median (lower quartile-upper quartile); n (%). 
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Table 2. Performance in the testing set of example MI3 threshold values from the training set 
 
TRAINING TESTING 
Statistical thresholds MI3 threshold 
(95%CI) 
Proportion 
low risk, % 
Proportion 
high risk, % 
MI3 
threshold 
Sensitivity NPV Specificity PPV Proportion 
low risk, % 
Proportion 
high risk, % 
Sensitivity ≥99.0% 1.6 
(0.9-3.0) 
59.8% 
(57.9-61.5%) 
- 1.6 97.8% 
(96.8-98.7%) 
99.7% 
(99.5-99.8%) 
77.4% 
(76.4-78.4%) 
33.9% 
(32.0-35.8%) 
69.4% 
(68.4-70.4%) 
- 
NPV ≥99.5% 3.1 
(1.7-4.7) 
68.6% 
(66.9-70.2%) 
- 3.1 95.8% 
(94.3-97.0%) 
99.4% 
(99.2-99.6%) 
83.6% 
(82.7-84.4%) 
40.9% 
(38.9-43.1%) 
75.2% 
(74.2-76.1%) 
- 
Specificity ≥90% 17.2 
(13.8-21.2) 
- 20.7% 
(19.2-22.1%) 
17.2 88.7% 
(86.7-90.8%) 
98.6% 
(98.3-98.8%) 
91.7% 
(91.1-92.3%) 
56.0% 
(53.3-58.5%) 
- 16.8% 
(16.0-17.7%) 
PPV of ≥75% 49.7 
(36.6-60.0) 
- 12.8% 
(11.6-14.0%) 
49.7 71.5% 
(68.4-74.3%) 
96.6% 
(96.2-97.0%) 
96.7% 
(96.3-97.1%) 
71.7% 
(68.9-74.8%) 
- 10.6% 
(9.9-11.2%) 
NPV = negative predictive value, PPV = positive predictive value 
Note: Sensitivity and NPV thresholds divide the population into low-risk and not low-risk groups (i.e. they do not determine a high-risk group). Similarly, specificity 
and PPV thresholds divide the population into high-risk and not high-risk groups (i.e. they do not determine a low-risk group. 
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Figure Legends 
 
Figure 1. Calibration and discrimination of the MI3 algorithm. (a) Calibration of the MI3 
algorithm with the observed proportion of patients with type 1 myocardial infarction in the 
test data set. Each point represents 100 patients.  The dashed lines represent perfect 
calibration. (b) Receiver-operating-characteristic curve showing discrimination of the MI3 
algorithm in the test data set. Some MI3 values shown for illustrative purposes only. 
 
Figure 2. Performance of MI3 algorithm compared to the ESC 3-hour algorithm 
Performance of MI3 at example thresholds (a) and the European Society of Cardiology (ESC) 
3-hour algorithm (b) for high-sensitivity cardiac troponin I (hs-cTnI) in 1,652 patients with 
≥2.5 hours between serial samples in the test set. URL = upper reference limit 
 
Figure 3. Performance of MI3 algorithm compared to the ESC 1-hour algorithm 
Performance of MI3 at example thresholds (a) and the European Society of Cardiology (ESC) 
1-hour algorithm (b) for high-sensitivity cardiac troponin I (hs-cTnI) in 336 patients with 
>0.5 hour but ≤1.5 hours between serial samples in the test set. 
 
Figure 4. MI3  clinical decision support tool to estimate the likelihood of myocardial 
infarction for individual patients 
A mock-up of how the MI3 algorithm may be presented to physicians and patients. The top 
row illustrates a low-risk patient, the middle row an intermediate risk and the bottom row a 
high-risk patient based on the example MI3 values of 0.9, 8.2 and 68.2 respectively. The 
screens on the left are for data input and return the MI3 value and estimated diagnostic 
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metrics for an individual patient. A screen swipe presents the data in a natural frequency 
number and graphical format for the patient. 
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